Egypt’s medical tourism revenue rose sharply in 2025, and the Egypt Healthcare Authority has now put a figure on the surge. Daily News Egypt reported that the Authority recorded roughly $8 million in medical tourism revenue for the year, drawn from medical and treatment services provided to about 35,000 international patients. Those international patients came from 124 countries, a spread the report presented as evidence of broad and diversified demand for Egyptian care. Daily News Egypt framed 2025 as a step change rather than a routine annual gain, and the headline figure carried the weight of that claim.
The comparison with the previous year is where the momentum shows. The Egypt Healthcare Authority reported that medical tourism revenue climbed 76.67 per cent against 2024, when the same services generated $3.7 million. Ahmed Elsobky, Chairperson of the Egypt Healthcare Authority, tied the increase to improvements across the facilities the Authority manages and to rising confidence among international patients. Elsobky attributed the jump to those operational upgrades rather than to any single marquee project, which is the more durable kind of growth if the trajectory holds.
Reading Egypt’s 76.67 per cent against a small base
That percentage is arresting, and it deserves to be read against the base it grew from. A move from $3.7 million to $8 million is a large proportional gain precisely because the starting figure was modest, and $8 million remains a small sum beside the billions that mature medical tourism destinations such as Thailand, Turkey and India report each year. The 76.67 per cent shows direction, not the size of the prize. The base is still small. Egypt is early in a long climb.
The composition matters more than the growth rate here. Serving 35,000 international patients from 124 countries is real diversification, because it spreads the Egypt Healthcare Authority across many source markets rather than leaving it tied to one or two. Concentration in a single source market is one of the standard risks in cross-border care, and a destination that draws from 124 countries is more resilient to a slump in any of them. Destinations at this stage tend to compete across a familiar spread of specialities, orthopaedics, oncology, cardiology, reconstructive surgery, fertility and dentistry, and the mix a destination wins shapes its economics. Orthopaedic and oncological work travels well, because long waiting lists at home push patients abroad. Egypt competes on cost and on speed. A per-country and per-speciality breakdown would sharpen the picture, and Elsobky would strengthen his own case by publishing one.
What the branded promise still has to prove
Egypt’s strategy is built around a public promise. The Egypt Healthcare Authority has chosen to lead with a brand, and the report set out an approach organised under the slogan “In Egypt, We Care”, supported by campaigns to attract international patients, by treatment packages benchmarked against international standards, and by an integrated digital system that carries each patient from first inquiry through to post-operative care. Every one of these is reasonable, and every one leans on the same condition, that the clinical machinery beneath the brand delivers steady outcomes.
Branding is the easy half of building a medical tourism destination. It is not the half that earns repeat referrals. International patients travel for outcomes and safety, and the drivers of that travel are cost, speed, access and the chance of treatment they cannot get at home. A slogan does none of that work. The digital system is the more telling of the three moves, because a patient who moves from inquiry to booking to aftercare without friction is more likely to finish the journey and to recommend it, and that quiet machinery is what turns a campaign into revenue.
Why the insurance and broker partnerships are the real test
The most instructive part of the report is where the Egypt Healthcare Authority intends to grow next. Daily News Egypt reported that the Authority plans to expand through partnerships with private insurers and brokerage firms, with the stated aim of raising the flow of international patients, lifting the sector’s returns, and cementing Egypt as a regional and global medical tourism hub. This is the line that matters, because insurers and brokers sit at the chokepoint where most cross-border care decisions are made or lost.
Insurers and brokers act as facilitators, and facilitators shape demand by deciding which destinations they route patients toward and on what terms. For a facilitator, the real choice is which orthopaedic or oncological unit gets the booking. For Egypt, an insurer deal removes two of the largest barriers international patients face, the cost of care abroad and the paperwork in between. The risk in leaning on facilitators is a familiar one across medical tourism, that middlemen end up selling visibility over verified quality of care. So the test for Elsobky is narrow. The 76.67 per cent becomes a base to build on only if these partnerships route patients toward accredited facilities with published outcomes and recognised accreditation, and not toward whichever providers pay for placement.
Egypt has reported a genuine result, and the spread behind it is real. The work is now local. Elsobky faces the harder task, turning an $8 million figure and a neat slogan into durable, accredited capacity that international patients return to and recommend.
